Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls
- 27 Downloads
Immunochemotherapy has long been the backbone of all treatment for B‑cell non-Hodgkin lymphoma. These therapies led to long-term disease control or even cure for some patients. However, these treatments also caused—sometimes severe—toxicities and deterioration of the quality of life. Novel agents targeting the B‑cell-receptor pathway and bcl2 have made great inroads in the treatment of mature lymphoid neoplasms. These new agents present themselves with a wide variety of new toxicities, which have to be taken into account when being administered to our patients. Hematological toxicities are very common. All new agents lead to various levels of immune suppression or immune modulation, which is often not easily quantifiable. Opportunistic infections such as progressive multifocal leukoencephalopathy, pneumocystis pneumonia, other mycotic infections, cytomegalovirus infections and pneumocystis pneumonia have been described, sometimes with fatal outcome. Ibrutinib shows increased risk of atrial fibrillation. It also increases the risk of bleeding, making the proper anticoagulatory management of patients developing atrial fibrillation under treatment a challenge. Idelalisib causes severe, sometimes fatal immune-mediated end-organ toxicities, especially colitis, pneumonitis, and transaminitis. Copanlisib leads to metabolic changes, namely episodes of hyperglycemia and arterial hypertension. Venetoclax has caused clinically significant tumor lysis syndrome. The introduction of a prolonged ramp-up phase of step wise dose escalation has decreased the rate of clinically significant tumor lysis syndrome. The drug also causes high rates of hematological toxicities, especially neutropenia.
KeywordsIbrutinib Idelalisib Venetoclax Tumor lysis syndrome BTK inhibitor
Conflict of interest
T. Spanberger declares that he has no competing interests.
- 1.Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2015. Bethesda: National Cancer Institute; 2018. based on November 2017 SEER data submission, posted to the SEER web site. https://seer.cancer.gov/csr/1975_2015.Google Scholar
- 7.Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24(Suppl 2):S53–S70.CrossRefGoogle Scholar
- 10.Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed algorithm for managing Ibrutinib-related atrial fibrillation. Oncology (Williston Park, NY). 2016;30(11):970–4–980–1, C3.Google Scholar
- 17.Sehn LH, Hallek M, Jurczak W, Brown JR, Barr PM, Catalano J, Coutre SE, Furman RR, Lamanna N, Loïc Y, Zelenetz AD, Sharman JP, DeVos S, Adewoye AH, Yeonhee K, Flinn IW, Salles GA. A retrospective analysis of pneumocystis Jirovecii pneumonia infection in patients receiving Idelalisib in clinical trials. Blood. 2018;128(22):3705. http://www.bloodjournal.org/content/128/22/3705.Google Scholar
- 18.Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park, NY). 2017;31(11):821–8.Google Scholar